FAQ for potential investors

 
 

Is IP solid?

BioFilm Technologies has a very solid IP protection

It shelters 10 patents delivered in 80 countries. First ones are already granted worldwide.

A fully positive ‘Free To Operate’ extensive study has been done, which means that no external patent can prevent us from developing.

IP is sheltered in a specific Luxemburg IP-Box belonging to BioFilm Technologies.

 
 

What about competition?

There is virtually no direct competition, the Biofilm Ring Test being the only efficient robot technology to test biofilms.

 
 
 

Why was not such an important field as biofilm bacteria behavior been more studied before?

Simply because nobody found, before BioFilm Technologies, how to manipulate biofilm with pipettors and lab robots.

This also simply explains why all existing antibiotics were discovered and developed to target the bacteria in their ephemeral swimming “planktonic” behavior.

 
 
 

What is the exit strategy?

BioFilm Technologies is committed to create attractive exit options for its investors within a horizon of 5 to 7 years, e.g. through an IPO, a Series B round or liquidity events at BioFilm Control or BioFilm Pharma level.

Clearly identified milestones will trigger exit opportunities :

  • BioFilm Control diagnostics market launch in France with social security reimbursment (2022)

  • BioFilm Control diagnostics international license agreements (2023/2024)

  • BioFilm Pharma Phase IIA/IIB milestones on one or several drugs (2025)